Ladd Delano 4

What Happened

• Ladd Delano, Executive Vice President and General Counsel of HealthEquity, was granted a total of 35,608 restricted stock units (RSUs) on March 25, 2026. The filing shows two awards: 15,157 RSUs and 20,451 RSUs, each recorded as acquisition type "A" at $0.00 per share (standard for RSU grants — no cash paid).
• Per the filing, 20,451 of those RSUs vested on March 25, 2026 (footnote F2). The remaining 15,157 RSUs are subject to a scheduled vesting plan (see Key Details).

Key Details

• Transaction date(s): March 25, 2026.
• Transaction type/code: Grant/Award (A); acquisition price reported $0.00 per RSU.
• Shares granted: 15,157 RSUs (unvested) and 20,451 RSUs (vested on 3/25/2026); total = 35,608 RSUs.
• Vesting: Footnote F1 — the 15,157 RSUs vest 25% on April 1, 2027, then 6.25% on the first day of each calendar quarter for the following 12 quarters. Footnote F2 — 20,451 RSUs vested on March 25, 2026.
• Shares owned after transaction: Not specified in this Form 4 filing.
• Filing date: March 27, 2026 (filed two days after the reported transactions).
• Notes: RSUs are contingent rights to receive common stock upon vesting; recorded acquisition price of $0 reflects a non-cash equity award, not a market purchase or sale.

Context

• This report documents equity awards and an immediate vesting of a portion of those awards — not an open‑market purchase or sale. Awards signal company compensation actions rather than direct insider buying/selling of stock.
• For retail investors, vested RSUs can increase an insider’s share holdings when settled, but do not necessarily indicate a personal purchase decision.